Acuta Capital Partners’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-197,000
| Closed | -$3.85M | – | 45 |
|
|
2024
Q3 | $3.85M | Buy |
197,000
+34,000
| +21% | +$664K | 3.12% | 12 |
|
|
2024
Q2 | $3.36M | Buy |
163,000
+73,000
| +81% | +$1.5M | 2.83% | 14 |
|
|
2024
Q1 | $1.92M | Sell |
90,000
-611,349
| -87% | -$13M | 1.25% | 23 |
|
|
2023
Q4 | $10.1M | Sell |
701,349
-744
| -0.1% | -$10.7K | 5.68% | 4 |
|
|
2023
Q3 | $6.4M | Sell |
702,093
-7,025
| -1% | -$64.1K | 4.29% | 9 |
|
|
2023
Q2 | $7.5M | Buy |
709,118
+143,861
| +25% | +$1.52M | 5.08% | 4 |
|
|
2023
Q1 | $6.91M | Buy |
565,257
+63,757
| +13% | +$780K | 5.09% | 7 |
|
|
2022
Q4 | $6.22M | Sell |
501,500
-35,000
| -7% | -$434K | 3.83% | 12 |
|
|
2022
Q3 | $7.33M | Hold |
536,500
| – | – | 3.16% | 11 |
|
|
2022
Q2 | $9.83M | Buy |
536,500
+62,531
| +13% | +$1.15M | 5.48% | 4 |
|
|
2022
Q1 | $7.62M | Buy |
473,969
+182,085
| +62% | +$2.93M | 3.56% | 9 |
|
|
2021
Q4 | $4.09M | Hold |
291,884
| – | – | 1.72% | 19 |
|
|
2021
Q3 | $5.47M | Sell |
291,884
-61,514
| -17% | -$1.15M | 1.93% | 17 |
|
|
2021
Q2 | $7.37M | Sell |
353,398
-183,422
| -34% | -$3.82M | 2.94% | 10 |
|
|
2021
Q1 | $15.2M | Sell |
536,820
-100,680
| -16% | -$2.85M | 5.47% | 3 |
|
|
2020
Q4 | $20.8M | Sell |
637,500
-335,500
| -34% | -$11M | 5.67% | 3 |
|
|
2020
Q3 | $29.8M | Buy |
973,000
+100,500
| +12% | +$3.08M | 8.1% | 2 |
|
|
2020
Q2 | $14.2M | Buy |
872,500
+674,500
| +341% | +$11M | 4.11% | 6 |
|
|
2020
Q1 | $1.97M | Sell |
198,000
-42,000
| -18% | -$418K | 0.95% | 28 |
|
|
2019
Q4 | $3.3M | Buy |
240,000
+145,000
| +153% | +$1.99M | 0.82% | 25 |
|
|
2019
Q3 | $1.44M | Buy |
+95,000
| New | +$1.44M | 1.04% | 19 |
|